"Graft vs Leukemia Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunological rejection of leukemia cells following bone marrow transplantation.
| Descriptor ID |
D020544
|
| MeSH Number(s) |
G12.875.402.320.320
|
| Concept/Terms |
Graft vs Leukemia Effect- Graft vs Leukemia Effect
- Graft-vs-Leukemia Response
- Graft-vs-Leukemia Responses
- Response, Graft-vs-Leukemia
- Responses, Graft-vs-Leukemia
- Graft vs Leukemia Response
- Graft-vs-Leukemia Effect
- Effect, Graft-vs-Leukemia
- Effects, Graft-vs-Leukemia
- Graft-vs-Leukemia Effects
|
Below are MeSH descriptors whose meaning is more general than "Graft vs Leukemia Effect".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Leukemia Effect".
This graph shows the total number of publications written about "Graft vs Leukemia Effect" by people in this website by year, and whether "Graft vs Leukemia Effect" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Graft vs Leukemia Effect" by people in Profiles.
-
Reduced dose of PTCy followed by adjuvant a-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Sci Rep. 2021 06 23; 11(1):13125.
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
-
ATG5-Dependent Autophagy Uncouples T-cell Proliferative and Effector Functions and Separates Graft-versus-Host Disease from Graft-versus-Leukemia. Cancer Res. 2021 02 15; 81(4):1063-1075.
-
Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
-
Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. Front Immunol. 2018; 9:1110.
-
Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. Haematologica. 2016 05; 101(5):e204-8.
-
Host CD8a+ dendritic cells may be a key factor for separating graft-versus-host disease from graft-versus-leukemia. Biol Blood Marrow Transplant. 2015 Apr; 21(4):775-6.
-
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83.
-
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):e105-9.
-
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013 Jul; 27(7):1538-47.